

CH. PERVAIZ ELAHI INSTITUTE OF CARDIOLOGY, MULTAN





MINUTES OF GRIEVENCE COMMITTEE MEETING

Agenda: Redressal of grievances received regarding technical evaluation of technical bids for the procurement of drugs/medicines through annual tender for the financial year 2025-26.

Venue: Office of the Professor of Cardiology, CPEIC Multan

Date & Time: Thursday 10-07-2025 at 10:00 AM

1. The following officers / members of the committee attended the meeting.

i. Prof. Dr. Tariq Abbas Professor of Cardiology	Chairman	
ii. Prof. Dr. Muhammad Younas Professor of Paediatric Cardiology	Member	
iii. Dr. Muhammad Moeen Associate Professor of Cardiac Surgery	Member	
iv. Dr. Usman Riaz Assistant Professor of Paediatric Cardiac Surgery	Member	
v. Dr. Syeda Farzana Batool Consultant Anaesthetist	Member	
vi. Dr. Umama Saeed Assistant Professor of Radiology	Member	
vii. Dr. Shah Zaman Additional Medical Superintendent	Member	

2. The following aggrieved bidders or their representatives attended the meeting on behalf of their respective firms/companies (attendance of meeting attached).

i. M/s Allied Distributors	ii. M/s Atco Laboratories Ltd.	iii. M/s B.Bruan Pakistan (Pvt) Ltd.
iv. M/s Bajwa Pharmaceuticals (Pvt) Ltd.	v. M/s Highnoon Laboratories Ltd.	vi. M/s Hiranis Pharmaceuticals (Pvt) Ltd.
vii. M/s Kaizen Pharmaceuticals (Pvt) Ltd.	viii. M/s Kohinoor Industries	ix. M/s Lucky Core Industries Ltd.
x. M/s Maple Pharmaceuticals (Pvt) Ltd.	xi. M/s Martin Dow Marker Ltd.	xii. M/s Mega Pharma (Pvt) Ltd.
xiii. M/s Rotex Pharma (Pvt) Ltd.	xiv. M/s Scilife Pharma (Pvt) Ltd.	xv. M/s Shazeb Pharmaceutical Industries Ltd.
xvi. M/s The Searle Company Ltd.		

3. The meeting started with the name of Allah, the Most Gracious and the Most Merciful. The Incharge Pharmacist (Medicines Procurement) presented the Technical Evaluation Report of drugs/medicines for the F.Y. 2025-26 and briefed the grounds of Responsiveness or Non-Responsiveness of a firm as whole or any individual quoted item by a specific bidder out of its all-quoted items in accordance with the advertised Evaluation Criteria. The Chairman appraised the efforts of Technical Evaluation Committee for evaluating huge file to conclude the detailed technical evaluation report.

4. The non-responsive technical offers of aggrieved bidder were discussed in detail with the members of the Grievance Committee. The submission / presentations of aggrieved bidders in response to the technical rejection were also discussed one-by-one in the light of Technical Evaluation Criteria; the contents of the already submitted technical bids and the documents / supporting presented in the grievance submission. The aggrieved bidders or their representative also appeared before the committee one-by-one to present and elaborate its stance before the committee. The committee after detailed deliberation, discussion and review of the documents / records presented by the aggrieved bidders concluded as follows:

T.E #	Quoted Item Name	Reason for Technical Rejection	Grievance / Reply of Firm	Proceedings, Discussions & Recommendations	Decision of Grievance Committee
1. M/s Allied Distributor					
128	Inj. Pofol 200mg/20ml	The firm attached ambiguous/illegible certificate of JpMHLW for Inj. Pofol and US-FDA certificate for Restane 100ml	The firm presented detailed annexures of JpMHLW certificate and also presented valid US-FDA certificate with screenshot from the US-FDA Website	The committee expressed satisfaction over the submitted documents / clarification and recommended to accept the grievance of the firm. The Incharge Pharmacist presented that the quoted brands offered by the firm qualifies Ordinary Parameters and qualifying marks as per Technical Evaluation Criteria.	The Committee accepted the grievance and both the brands offered by M/s Allied Distributor were declared "Technically Responsive" unanimously.
129	Restane 100ml				
2. M/s Atco Laboratories Ltd.					
63	Inj. Aggrastat 12.5mg/50ml	The quoted brand achieved 43 marks and failed to achieve qualifying marks (48.75 out of 75)	The firm presented agency agreement between Atco Labs and its principal and requested to consider its marks in bid evaluation	The committee recommended to re-evaluate the marks after considering the presented document of 10 marks. It was concluded that after acquiring 10 marks the quoted brand will qualify 53 marks out of 75	The Committee accepted the grievance and Inj. Aggrastat was declared "Technically Responsive" unanimously.

[Handwritten signatures and initials]

3. M/s B. Braun Pakistan (Pvt) Ltd.

109	Gelofusine 4% 500ml Infusion	No valid certificate of WHO/JpMHLW/EMA/US-FDA was attached in the bid	The representative presented eudra-GMP Certificate of the manufacturer and claimed that it reflects that EMA status of the quoted brand	The Chairman responded that eudra-GMP Certificate is also invalid and valid upto 31.08.2020 only. The representative failed present any valid document in the meeting to ascertain its claim	The Committee rejected the grievance and recommended to uphold the decision of Technical Evaluation Committee, CPEIC Multan
-----	---------------------------------	---	---	---	--

4. M/s Bajwa Pharmaceuticals (Pvt) Ltd.

3 12 22 42 43 51 52 78 130 132	Inj. Clopramid Inj. Digoxin Inj. Baligno Inj. Glynitrin Inj. Isobaj Inj. Bopamin Inj. Dobutine Inj. Valproate Inj. Relocurium Inj. Trocuronium	Invalid cGMP Certificate attached (expired on 14.02.2025) and No Satisfactory Inspection Report attached. The firm applied for issuance of revalidated cGMP Certificate and documents attached with the bid.	The representative presented documents i.e. request for renewal of cGMP Certificate and paid Challan and submitted that firm had applied for renewal in time and as per DRAP officials, inspection is expected in next week. He requested that as the firm is responsive in Central Procurement Tender and other teaching hospitals in Punjab on submission of these documents so firm may be considered responsive in CPEIC as well.	The Chairman and other members asked for the documentary evidence of responsiveness in Central Procurement Tender and other teaching hospitals and the representative presented technical reports. Dr. Shah Zaman asked the firm to submit an affidavit that renewal is in process and firm will provide revalidated cGMP Certificate as soon as issued by DRAP. Moreover, no Purchase Order will be issued to the firm till the receipt of revalidated cGMP Certificate. The firm submitted this affidavit in next day.	The committee after detailed deliberation rejected the grievance of M/s Bajwa Pharmaceuticals due to failure to comply Compulsory Parameter clause-iii and also in terms of falsified affidavit required under Compulsory Parameter Clause-ix of the advertised bidding documents in reference to the minutes of GRC decision of SHC&MED Lahore vide No. SO(P-I)H/1-4/2024-25 dated: 15.07.2025
---	---	--	---	---	--

5. M/s Highnoon Laboratories Ltd.

25 44 59	Tab. Blokium 50mg Tab. Herbesser 60mg Tab. Loprin 75mg	The quoted brands achieved 50 marks and failed to achieve qualifying marks (52 out of 80)	The firm presented documents of availability in chain pharmacies and requested to consider its marks (05 marks) in bid evaluation	The committee recommended to re-evaluate the marks after considering the presented documents of 05 marks. It was concluded that after acquiring 05 marks the quoted brands will qualify 55 marks out of 80.	The Committee accepted the grievance and the quoted brands of Highnoon Laboratories were declared "Technically Responsive" unanimously.
----------------	---	--	---	---	---

6. M/s Hiranis Pharmaceuticals (Pvt) Ltd.					
65	Tab. Rosuvast 10mg	The quoted brand achieved 46 marks and failed to achieve qualifying marks (52 out of 80)	The firm presented documents Water Treatment Plant (03 marks) & Chain Pharmacies (02 marks) and requested to consider its marks (05 marks) in bid evaluation	The committee recommended to re-evaluate the marks after considering the presented documents of 08 marks. It was concluded that after acquiring 05 marks the quoted brands will qualify 51 marks and failed to qualify passing marks even in grievance meeting	The Committee rejected the grievance and recommended to uphold the decision of Technical Evaluation Committee, CPEIC Multan
7. M/s Kaizen Pharmaceuticals (Pvt) Ltd.					
33	Tab. Ivable 5mg	The quoted brand achieved only 13 marks and failed to achieve qualifying marks (52 out of 80)	The firm presented missing documents and requested to consider its marks in bid evaluation	The committee recommended to re-evaluate the marks after considering the presented documents. After evaluation of presented documents, it was concluded that presented documents also failed to add sufficient marks for qualifying even in grievance meeting	The Committee rejected the grievance and recommended to uphold the decision of Technical Evaluation Committee, CPEIC Multan
8. M/s Kohinoor Industries					
125	Prodine Solution 450ml	Affidavit (Bid Form 8.6) was not attached in the bid. The quoted brands obtained 47 marks and failed to achieve qualifying marks (52 out of 80)	The firm presented Bid Form 8.6 and documents of Water Treatment Plant (03 marks) & availability in Chain Pharmacies (03 marks) and requested to consider its marks (08 marks) in bid evaluation	The committee recommended to re-evaluate the marks after considering the presented documents of 08 marks. After evaluation of presented documents, it was concluded that after acquiring 08 marks the quoted brands will qualify 55 marks out of 80.	The Committee accepted the grievance and the quoted brands of Kohinoor Industries were declared "Technically Responsive" unanimously.
126	Prodine Scrub 450ml				
9. M/s Lucky Core Industries Ltd.					
94	Susp. Azocyd	The quoted brands obtained 49 marks and failed to achieve qualifying marks (52 out of 80)	The firm presented documents regarding FDA Approval of API Source requested to consider its marks (05 marks) in bid evaluation	The committee recommended to re-evaluate the marks after considering the presented documents of 05 marks. After evaluation of presented documents, it was concluded that after acquiring 05 marks the quoted brands will qualify 54 marks out of 80.	The Committee accepted the grievance and the quoted brands at Tender Sr. No. 94, 96,97, 98 & 100 were declared "Technically Responsive" unanimously.
96	Inj. Stanem 500mg				
97	Inj. Merpen 500mg				
98	Inj. Merpen 1g				
100	Inj. Hy-Cortisone				

10. M/s Maple Pharmaceuticals (Pvt) Ltd.


35	Tab. Capril 25mg	The quoted brands obtained less marks and failed to achieve qualifying marks (52 out of 80)	The firm presented following documents and requested to consider its marks in bid evaluation i. IQVIA Product Data of all quoted products (3 marks) ii. Delivery Challans of Tab. Losaan 50mg (10 marks) iii. Chain Pharmacies data of Tab. Calzem 60mg (5 marks)	The committee recommended to re-evaluate the marks after considering the presented documents. After evaluation of presented documents, it was concluded that after acquiring marks of accepted documents the quoted brands will qualify passing marks.	The Committee accepted the grievance and the quoted brands at Tender Sr. No. 35, 37,40, 41 & 44 were declared “Technically Responsive” unanimously.
37	Tab. Losaan 50mg				
40	Tab. Glyrate 2.6mg				
41	Tab. Glyrate 6.4mg				
44	Tab. Calzem 60mg				

11. M/s Martin Dow Marker Ltd.

31	Tab. Concor 5mg	The quoted brands obtained less marks and failed to achieve qualifying marks (52 out of 80)	The representative presented following documents and requested to consider its marks in bid evaluation i. Summary of Private Sector Sale on Stamp Paper (10 marks) ii. Valid Calibration Certificate of Stability Chambers (6 marks) iii. Accelerated Stability Studies Data (1 mark)	The committee recommended to re-evaluate the marks after considering the presented documents. After evaluation of presented documents, it was concluded that after acquiring marks of accepted documents the quoted brands will qualify passing marks except Tab. Crescor 10mg (47 out of 80 marks only)	The Committee accepted the grievance and the quoted brands at Tender Sr. No. 31, 45 & 100 were declared “Technically Responsive” unanimously.
45	Tab. Lodopin 5mg				
65	Tab. Crescor 10mg				
100	Tab. Glioptium 2mg				

12. M/s Mega Pharmaceuticals Ltd.

25	Tab. ATL 50mg	Invalid cGMP Certificate attached (expired on 21.03.2025) and No Satisfactory Inspection Report attached. The firm applied for issuance of revalidated cGMP Certificate and attached documents with the bid.	The representative presented revalidated cGMP Certificate and data regarding public sector sale of quoted brands and requested to consider cGMP Certificate and marks in bid evaluation.	The committee accepted the revalidated cGMP Certificate and recommended to re-evaluate the marks after considering the presented documents. After evaluation of presented documents, it was concluded that after acquiring 10 marks of public sector experience the quoted brands will qualify passing marks	The Committee accepted the grievance and the quoted brands of M/s Mega Pharmaceuticals were declared “Technically Responsive” unanimously.
37	Tab. Megasar 50mg				
45	Tab. Megadip 5mg				



13. M/s Rotex Pharma (Pvt) Ltd.


43	Inj. Isodil-D	The quoted brands obtained less marks (32 & 34 respectively) and failed to achieve qualifying marks (52 out of 80)	The representative presented documents and claimed that these documents were already attached with the technical bid however may be overlooked and presented parameter wise marks to support its claim.	The committee recommended to re-evaluate the marks after considering the presented documents in grievance to verify claim of firm. After evaluation of presented documents, it was concluded that presented documents also failed to add sufficient marks for qualifying even in grievance meeting.	The Committee rejected the grievance and recommended to uphold the decision of Technical Evaluation Committee, CPEIC Multan
63	Inj. Rotastat				

14. M/s Scilife Pharma (Pvt) Ltd.

58	Inj. Scinoxa 60mg	No valid certificate of WHO/JpMHLW/EMA/US-FDA and no evidence of Bio-similarity study lab accreditation was attached in the bid. Moreover, the quoted brand failed to achieve qualifying marks (48.75 out of 75)	The representative presented eudra-GMP Certificate of the manufacturer and claimed that it reflects that EMA status of the quoted brand. It claimed that "Clantha Research Ltd. India" is FDA approved Lab for Bio-similarity study of Enoxaparin Sod.	The Chairman & Dr. Shah Zaman required documentary evidence of its claim that eudra-GMP Certificate is equivalent to EMA Certificate. The representative failed present any valid document in the meeting to ascertain its claim	The Committee rejected the grievance and recommended to uphold the decision of Technical Evaluation Committee, CPEIC Multan
----	-------------------	--	---	---	--

15. M/s Shazeb Pharmaceutical Industries (Pvt) Ltd.

107 108 111 112 113 114 115 116 117 118	All quoted brands by M/s Shazeb Pharmaceuticals (Pvt) Ltd.	Invalid cGMP Certificate attached (expired on 31.05.2024) and No Satisfactory Inspection Report attached. Moreover, the quoted brands failed to achieve qualifying marks (52 out of 80)	The representative presented cGMP Certificate and other documents (valid ISO 14001, ISO 17025 certificates of 6 marks and technical staff data) and requested to consider cGMP Certificate and marks in bid evaluation.	The committee accepted the revalidated cGMP Certificate and recommended to re-evaluate the marks after considering the presented documents. After evaluation of presented documents, it was concluded that only ISO Certificates fulfill the parameters and acquire 3+3 marks while other documents are still insufficient to qualify any marks.	The Committee accepted the grievance and the quoted brands of M/s Shazeb Pharma only at Tender Serial No. 111, 115, 116 & 117 were declared "Technically Responsive" unanimously.
--	--	---	---	---	---




16. M/s The Searle Company Ltd.

40	Tab. Sustac 2.6mg	The quoted brands obtained less marks (48 & 45 respectively) and failed to achieve qualifying marks (52 out of 80)	The representative presented revised affidavit for Summary of Private Sector Sales Experience with the excuse that earlier provided affidavit was misprinted as sale was given in packs instead of units. Now the revised affidavit has been prepared on unit sales which fulfill the required quantity of market experience. He requested to consider its marks in bid evaluation.	The committee recommended to re-evaluate the marks after considering revised affidavit in the grievance. After evaluation and discussion with the members, it was concluded that after acquiring 10 marks of Pvt. Sector experience the quoted brands will qualify passing marks (55 out of 80)	The Committee accepted the grievance and the quoted brands at Tender Sr. No. 40 & 41 were declared “Technically Responsive” unanimously.
41	Tab. Sustac 6.4mg				

5. The grievance filed by aggrieved bidders whose bids were not found on e-PADS or they uploaded technical bid in wrong LOT on e-PADS; was also discussed in detail and the committee concluded that as per Section I (Invitation to e-Bids) and ITB clause 2.4.1(vii) of Bidding Documents; bidders are required to submit e-bids in relevant lot(s) only and in case of failure on part of the bidder to submit e-bid due to any technical or internet issue and submission in irrelevant lot will result in rejection of bid. As no hard copy of bid is allowed in rules as an alternate of e-bid, therefore, the committee unanimously decided to disallow participation of such firms or bids in tendering process whose e-bid was not found on e-PADS and in the other case the committee recommended to consider only those lots against which the bidder uploaded e-bid(s)


6. The meeting ended with vote of thanks by the Chairman Grievance Committee.



Dr. Umama Saeed (Member)
Assistant Prof. of Radiology
CPEIC, Multan



Dr. Usman Riaz (Member)
Assistant Prof. of Paediatric Cardiac Surgery
CPEIC, Multan


Dr. Syeda Farzana Batool (Member)
Consultant Anaesthetist
CPEIC, Multan


Dr. Muhammad Moeen (Member)
Associate Prof. of Cardiac Surgery
CPEIC, Multan


Dr. Shah Zaman (Member)
Additional Medical Superintendent
CPEIC, Multan


Dr. Muhammad Younas (Member)
Professor of Paediatric Cardiology
CPEIC, Multan


Prof. Dr. Tariq Abbas
Chairman, Grievances Committee
Prof. of Cardiology, CPEIC, Multan